Our Science

OUR SCIENCE

Congress Presentations

This section includes posters and presentations related to Arvinas’ PROTAC science, discovery compounds, and clinical-stage assets presented at scientific congresses in the past three years.

ASCO 2025 | Chicago, IL

May 30 - Jun 3, 2025

Presentation
Vepdegestrant, a PROTAC Estrogen Receptor (ER) Degrader, vs Fulvestrant in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Results of the Global, Randomized, Phase 3 VERITAC-2 Study

EP Hamilton et al.

VIEW MATERIAL
VIEW SUMMARY

ASCPT 2025 | Washington, DC

May 28 - 31, 2025

Poster
The Effect of Carbamazepine on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Healthy Adults

H Wang et al.

VIEW MATERIAL

IAPRD 2025 | New York City, NY

May 7 - 10, 2025

Poster
First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ARV-102, a PROTAC LRRK2 Degrader, in Healthy Volunteers

L Smits et al.

VIEW MATERIAL

AACR 2025 | Chicago, IL

Apr 25 - 30, 2025

Poster
ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma Models

A Van Acker et al.

VIEW MATERIAL

AD/PD 2025 | Vienna, Austria

Apr 1 - 5, 2025

Presentation
First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ARV-102, a PROTAC LRRK2 Degrader, in Healthy Volunteers

L Smits et al.

VIEW MATERIAL

SABCS 2024 | San Antonio, TX

Dec 10 - 13, 2024

Poster
Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, Plus Abemaciclib in Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer: TACTIVE-U Preliminary Phase 1b Results

J Hilton et al.

VIEW MATERIAL
VIEW SUMMARY

SABCS 2024 | San Antonio, TX

Dec 10 - 13, 2024

Poster
Evaluating CYP3A4-Mediated Drug Interaction Risks for Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Combination With Cyclin-Dependent Kinase 4/6 Inhibitors and Everolimus

W Tan et al.

VIEW MATERIAL

SABCS 2024 | San Antonio, TX

Dec 10 - 13, 2024

Poster
Evaluation of the Combination of Vepdegestrant, a PROTAC Estrogen Receptor Degrader, Plus Palbociclib in CDK4/6 Inhibitor–Resistant Wild-Type and Estrogen Receptor Y537S–Mutant Patient-Derived Xenograft Models

J Teh et al.

VIEW MATERIAL

ACoP 2024 | Phoenix, AZ

Nov 10 - 13, 2024

Poster
Population Pharmacokinetic (PopPK) Model to Characterize Pharmacokinetics (PK) of Vepdegestrant, a Proteolysis Targeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in Healthy Adult Participants

SK Drescher et al.

VIEW MATERIAL
1 2 3 4 5 6 … 9